Sathornsumetee, S., Vredenburgh, J. J., Rich, J. N., Desjardins, A., Quinn, J. A., Mathe, A. E., … Reardon, D. A. (2008). Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme. JOURNAL OF CLINICAL ONCOLOGY, 26(15).

Sathornsumetee, S., J. J. Vredenburgh, J. N. Rich, A. Desjardins, J. A. Quinn, A. E. Mathe, S. Gururangan, A. H. Friedman, H. S. Friedman, and D. A. Reardon. “Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme.” JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).

Sathornsumetee S, Vredenburgh JJ, Rich JN, Desjardins A, Quinn JA, Mathe AE, et al. Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme. JOURNAL OF CLINICAL ONCOLOGY. 2008 May 20;26(15).

Sathornsumetee, S., et al. “Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme.” JOURNAL OF CLINICAL ONCOLOGY, vol. 26, no. 15, AMER SOC CLINICAL ONCOLOGY, May 2008.

Sathornsumetee S, Vredenburgh JJ, Rich JN, Desjardins A, Quinn JA, Mathe AE, Gururangan S, Friedman AH, Friedman HS, Reardon DA. Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2008 May 20;26(15).